Business · 05/06/2023Updated: 10/17/2026 · 1 min read
FDA Authorizes Emergency Use of GOHIBIC for COVID-19 Treatment
Summary
The US Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the drug product GOHIBIC (vilobelimab), developed by InflaRx GmbH, to treat COVID-19 during the ongoing pandemic, following a public health emergency declaration by the Secretary of Health and Human Services in March 2020.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →